AnaptysBio heads into the final stretch of Q3 with an unusual split signal — nearly one-in-five shares shorted against the most bullish options reading in months.
Short interest is the dominant structural feature here. Nearly 19.6% of the free float is held short, a level that has crept steadily higher over the past month — up roughly 0.8% across August and into September. The official FINRA settlement data through August 31 puts days-to-cover at 15.6, meaning shorts would need more than three weeks of average volume to fully unwind. That is a meaningful overhang. And yet the borrow market is not flashing distress. Availability has tightened meaningfully this week, falling from around 420% to 344% — still comfortably in the normal range but moving in the wrong direction for bears who might need to cover quickly. Cost to borrow dropped 22% on the week to just 0.44%, which is historically cheap and suggests the lending pool has not been squeezed. The ORTEX short score edged up to 69.3, a two-week high, tracking the slow grind higher in positioned short shares. The picture is one of patient, well-funded short conviction — not a panicked or expensive trade.
Options tell a sharply different story. The put/call ratio has collapsed to 1.01, more than two standard deviations below its 20-day mean of 1.41 — the most bullish reading in several months. A week ago the PCR was running at 1.64 on options expiry. This week's reset suggests fresh call-side positioning is arriving, even as short sellers show no sign of retreat. When a nearly 20% short-interest name attracts aggressive call buying, the setup is charged: shorts are dug in, but someone on the other side is betting they are wrong.
The Street leans constructive but has been trimming its ambitions. Analysts are broadly bullish — most recent changes maintain Buy or Outperform ratings — but price targets are sliding. Leerink Partners cut its target from $90 to $81 yesterday while keeping Outperform. TD Cowen trimmed from $75 to $70 in late August. The consensus mean now sits at $88.50 against a $53.92 close, implying 64% return potential. That gap is wide enough to keep bulls engaged, but the direction of travel on targets is clearly downward. Factor scores support the cautious optimism: EPS momentum ranks in the 93rd–94th percentile over both 30- and 90-day windows, and EPS surprise sits at the 93rd percentile — AnaptysBio has been beating estimates consistently. The short score rank of just 12 means the stock ranks poorly relative to peers on short-side pressure, confirming that the 19.6% float short is an outlier in sector context.
Institutional ownership adds another dimension worth watching. EcoR1 Capital holds a dominant 26.4% of shares — an extraordinary concentration for a stock this size. BlackRock added 162,669 shares through August, and State Street built a position by nearly 294,000 shares over the same period. On the other side, Sirenia Capital trimmed by 428,000 shares in the June quarter. The activist 13D/G register carries no current activist — the most recent notable exit was Fairmount Funds, which dropped from 5.5% to zero by February 2025. Stakes there are as-last-disclosed, and holders falling below 5% need not file again.
Earnings land on November 4. The three most recent prints produced moves of -2.3%, +6.6%, and -5.5% on the day — no consistent pattern, but the range is wide. With a short score near its recent high and call buyers arriving just as GSK litigation and pipeline uncertainty remain live, the November catalyst will matter more than most.
See the live data behind this article on ORTEX.
Open ANAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
